A Comparative Study of the Renoprotective Effects of Benidipine and Valsartan in Primary Hypertensive Patients with Proteinuria

 

 Buy Article Permissions and Reprints

Abstract

Objective:

To compare the renoprotective effects of the calcium channel blocker (CCB) benidipine (CAS 105979-17-7) and the angiotensin II receptor blocker (ARB) valsartan (CAS 137862-53-4) in primary hypertensive patients with proteinuria.

Methods:

236 patients with primary hypertension were randomly divided into different groups and were administered either benidipine or valsartan. The alterations of the glomerular filtration rate (GFR) and proteinuria were compared between the different groups.

Results:

Valsartan could decrease the level of proteinuria significantly as compared with that in benidipine-treated hypertensive patients with proteinuria at levels < 1 g/24 h (P < 0.01). There was no significant difference of the effects of benidipine and valsartan on proteinuria reduction in hypertensive patients with proteinuria at levels 1–3 g/24 h. There was no significant difference of the effects of benidipine and valsartan on GFR in benidipine- and valsartan-treated patients.

Conclusion:

The results showed that valsartan was more effective in decreasing the levels of proteinuria in hypertensive patients with proteinuria at an early stage of nephropathy. The renoprotective effects of benidipine and valsartan in primary hypertensive patients with proteinuria were similar.

• Literature

• 1 Matsuzaki G, Ishizaka N, Furuta K, Hongo M, Saito K, Sakurai R et al. Comparison of vasculoprotective effects of benidipine and losartan in a rat model of metabolic syndrome. Eur J Pharmacol. 2008; Jun; 587 (1–3) 237-242
  CrossrefPubMedGoogle Scholar
• 2 Takayama M, Arakawa E, Yao K, Ina Y, Sato H, Hawegawa K et al. Effects of combination of angiotensin receptor blocker and calcium channel blocker on ox-LDL levels and cardiovascular dysfunction in Dahl rats. Pharmacology. 2006; 77 (4) 179-187
  CrossrefPubMedGoogle Scholar
• 3 Shikata C, Sekikawa T, Kimura N, Kojima A, Seki S, Oka H et al. Beneficial effect of combination therapy with antihypertensive drugs in patients with hypertension. Exp Clin Cardol. 2007; 12 (1) 33-36
  PubMedGoogle Scholar
• 4 The Joint National Committee on Prevevtion, Detection Evaluation and Treatment of High Blood Pressure: The Sixth Report of the Joint National Committee on Prevevtion, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med. 1997; 157: 2413-46
  CrossrefPubMedGoogle Scholar
• 5 Mansia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et al. European Society of Hypertension; European Society of Cardiology. 2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press. 2007; 16 (3) 135-232
  CrossrefPubMedGoogle Scholar
• 6 Liu Lisheng. Guidelines for the management of hypertension in china. Clin J Hypertension. 2005; Feb; 12 (Suppl.) 9-10
  PubMedGoogle Scholar
• 7 Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatintine: A new prediction. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; Mar; 130 (2) 461-70
  CrossrefPubMedGoogle Scholar
• 8 National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Diseases: Evaluation, Classification and Stratification. Am J Kidney Dis. 2002; Feb; 39 (2 suppl 1) S1-S266
  CrossrefPubMedGoogle Scholar
• 9 Keane W, Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PAPADE): A position paper of the National Kidney Foundation. Am J Kidney Dis. 1999; May; 33 (5) 1004-10
  CrossrefPubMedGoogle Scholar
• 10 Uzu T, Nishimura M, Fujii T, Sakaguchi M, Kanasaki M, Isshiki K et al. Benidipine attenuates glomerular hypertension and reduces albuminuria in patients with metabolic syndrome. Hypertens Res. 2007; Feb; 30 (2) 161-5
  CrossrefPubMedGoogle Scholar
• 11 Akizuki O, Inayoshi A, Kitayama T, Yao K, Shirakura S, Sasaki K et al. Blockade of T-type voltage-dependent Ca²⁺ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R. Eur J Pharmacol. 2008; Apr; 584 (2–3) 424-34
  CrossrefPubMedGoogle Scholar
• 12 Seino H, Miyaguchi S, Yamazaki T, Ota S, Yabe R, Suzuki S. Effect of benidipine hydrochloride, a long-acting T-type calcium channel blocker, on blood pressure and renal function in hypertensive patients with diabetes mellitus. Analysis after switching from cilnidipine to benidipine. Arzneimittelforschung. 2007; 57 (8) 526-31
  Article in Thieme ConnectPubMedGoogle Scholar
• 13 Saito F, Fujita H, Takahashi A, Ichiyama I, Harasawa S, Oiwa K et al. Renoprotective effect and cost-effectiveness of using benidipine, a calcium channel blocker, to lower the dose of angiotensin receptor blocker in hypertensive patients with albuminuria. Hypertens Res. 2007; Jan; 30 (l) 39-47
  CrossrefPubMedGoogle Scholar
• 14 Hayashi K, Wakino S, Homma K, Sugano N, Saruta T. Pathophysiological significance of T-type Ca²⁺ channels: role of T-type Ca²⁺ channels in renal microcirculation. J Pharmacol Sci. 2005; Nov; 99 (3) 221-7
  CrossrefPubMedGoogle Scholar
• 15 Gotoh Y, Mruaki K, Imaizumi Y. Effects of benidipine, a 1,4-dihydropyridine derivative, on single L-type Ca channel currents in vascular smooth muscle. Clin Prep. 1992; 26: 3879-901
  PubMedGoogle Scholar
• 16 Shimada S, Nakajima Y, Yamamaoto K, Sawada Y, Iga T. Comparative pharmacodynamics of eight calcium channel blocking agents in Japanese essential hypertensive patients. Biol Pharm Bull. 1996; Mar; 19 (3) 430-7
  CrossrefPubMedGoogle Scholar
• 17 Tsuda K. Electron paramagnetic resonance investigation on modulatory effect of benidipine on membrane fluidity of erythrocytes in essential hypertension. Heart Vessels. 2008; Mar; 23 (2) 134-9
  CrossrefPubMedGoogle Scholar
• 18 Suzuki K, Imada T, Gao F, Ma H, Nagata T. Radioautographic study of benidipine hydrochloride. Localization in the mesenteric artery of spontaneously hypertensive rat. Arzneimittelforschung. 1994; Feb; 44 (2) 129-33
  PubMedGoogle Scholar
• 19 Morikawa T, Okumura M, Konishi Y, Okada N, Imanishhi M. Effects of benidipine on glomerular hemohynamics and proteinuria in patients with nondiabetic nephropathy. Hypertens Res. 2002; 25: 571-6
  CrossrefPubMedGoogle Scholar
• 20 Kimrua K. Effects of benidipine hydrochloride on renal arterioles. Ther Res. 1994; 15: 2237-40
  PubMedGoogle Scholar
• 21 Gashti CN, Bakris GL. The role of calcium antagonists in chronic kidney disease. Curr Opin Nephrol Hypertens. 2004; Mar; 13 (2) 155-61
  CrossrefPubMedGoogle Scholar
• 22 Inoue S, Tomino Y. Effcets of calcium antagonists in hypertensive patients with renal dyfunction: A protective, randomized, parallel trial comparing benidipine and nifedipine. Nephrology (Carlton). 2004; Oct; 9 (5) 265-71
  CrossrefPubMedGoogle Scholar
• 23 Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. New Engl J Med. 2001; Sep 20; 345 (12) 870-8
  CrossrefPubMedGoogle Scholar
• 24 Croom KF, Curran MP, Goa KL, Perry CM. Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy. Drugs. 2004; 64 (9) 999-1028
  CrossrefPubMedGoogle Scholar